De Novo Design in an M1 Positive Allosteric Modulator Backup Program: The Discovery of VU6069863
Open Access
- 21 August 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (9) , 2085-2094
Abstract
Recently, we disclosed our M1 PAM that had advanced into Phase I clinical studies, VU0467319, as well as a deuterated back-up compound, VU6045422, to address a major metabolite produced in man and improve tox profile. Ultimately, this series failed to overcome its liabilities and was terminated. However, the team was challenged with developing chemically distinct backup candidates without performing a new HTS campaign. De novo design strategies based upon the other two M1 ago-PAMs that had previously entered clinical development, MK-7622 and TAK-071, led to the discovery of a fundamentally new chemotype based on a 3,4-dihydrobenzo[f][1,4]oxazepin-5-(2H)-one core, providing VU6069863. VU6069863 proved to be an M1 PAM (EC50 = 248 nM, 87% ACh Max) with minimal M1 agonism, (EC50 > 30 μM, 19% ACh Max) despite being derived from potent M1 ago-PAM chemotypes, with good CNS penetration (rat Kp = 0.59, Kp,uu = 0.13, MDCK-MDR1 ER = 1.8, Papp = 32.8 × 10–6 cm/s) and pro-cognitive efficacy in both contextual fear conditioning (minimally effective dose [MED] = 0.1 mg/kg PO) and novel object recognition (MED = 1 mg/kg PO) in rats.Keywords
Funding Information
- National Institute of Mental Health (MH073676)
- National Institute of Mental Health (MH082867)
- National Institute of Mental Health (MH108498)
- National Institute of Mental Health (MH109498)
This publication has 27 references indexed in Scilit:
- Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical TrialsACS Chemical Neuroscience, 2024
- Discovery of VU6007496: Challenges in the Development of an M1 Positive Allosteric Modulator Backup CandidateACS Chemical Neuroscience, 2024
- Some key parameters in contextual fear conditioning and extinction in adult ratsBehavioural Brain Research, 2024
- Functional activity of the muscarinic positive allosteric modulator VU319 during a Phase 1 Single Ascending Dose studyThe American Journal of Geriatric Psychiatry, 2021
- Cognitive performance effects following a single dose of the M1 muscarinic positive allosteric modulator VU319Alzheimer's & Dementia, 2020
- Regulating human safety: How dose selection in toxicity studies impacts human health hazard assessment and subsequent risk management optionsRegulatory Toxicology and Pharmacology, 2020
- Design and Synthesis of γ- and δ-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist ActivityJournal of Medicinal Chemistry, 2017
- Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMsACS Chemical Neuroscience, 2017
- Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's diseaseDrug Discovery Today, 2013
- Muscarinic agonists and antagonists in the treatment of Alzheimer's diseaseIl Farmaco, 2001